Spondyloarthritis & psoriatic arthritis
Responsiveness of spondyloarthritis-specific health utilities based on the ASAS Health Index (U-ASAS-HI): an ancillary analysis from the ASAS-HI validation study
Authors' conclusion
In a context where change is expected, the SpA-specific U-ASAS-HI correlates as expected with changes in other SpA-specific outcomes and shows good responsiveness, which is similar to but not better than for generic utilities.
Study context
- Population
- Patients with spondyloarthritis (SpA) in the ASAS-HI international validation study starting TNF inhibitor (TNFi), csDMARD or NSAIDmean age 37 years
- Participants
- 219 patients
- Comparison
- U-ASAS-HI vs generic health utilities
- TNFin = 110
- csDMARDn = 37
- NSAIDn = 72
- Primary endpoint
- Responsiveness of U-ASAS-HI vs EQ-5D-5L and SF-6D: correlation of change in utility with change in external health anchors, SRM and Cohen's ES per treatment group, discrimination of BASDAI-50% (non)-responders
Methodological detailsancillary analysis, responsiveness analysis
- Ancillary analysis
- Responsiveness analysis
Primary result
As reported in the abstract
- Hypotheses on correlations of change scores confirmed for 75% of comparisons for U-ASAS-HI and EQ-5D-5L, but not for SF-6D
- Standardized response mean (SRM) and effect size (ES) for U-ASAS-HI large in TNFi, moderate in csDMARD and small to moderate in NSAID
- Hypothesized larger SRM and ES for U-ASAS-HI vs EQ-5D and SF-6D not consistently confirmed across the three treatment groups
- Discrimination between BASDAI-50% responders and non-responders did not differ among utility instruments in ROC comparison
Original publication
Responsiveness of spondyloarthritis-specific health utilities based on the ASAS Health Index (U-ASAS-HI): an ancillary analysis from the ASAS-HI validation study. Rheumatology (Oxford). Published 22 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →